The growth of some pancreatic cancers is fueled by fungus-induced production of the cytokine IL-33, and the progression of such tumors could be slowed down by treatment with antifungals or genetic deletion of IL-33, researchers reported in the February 3, 2022, online issue of Cancer Cell.
The prognosis for pancreatic cancer patients remains among the most dismal of any solid tumor, with 5-year-survival rates barely out of the single digits. Read more . . .